NCT06435845Phase 2Terminated

Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

Study sponsor: Rallybio

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-10-01Actual
Enrollment · participants1Actual
Source updated2026-03-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of Participants with treatment related adverse events as defined by CTCAE 5.0 Measure: Maternal exposure to RLYB212 as measured in serum. After: Measure: Number of Participants With Treatment Related Adverse Events as Defined by CTCAE 5.0 Measure: Maternal Exposure to RLYB212 as Measured in Serum.

Check registry source

· 1 field changed

Recruitment status changed

Before: Completed. After: Terminated.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 8 participants (planned). After: 1 participants (actual).

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview